Fate Therapeutics, Inc. · Transaction Jan 31, 2023 · Filed Feb 24, 2023 · $1,001 to $15,000
NASDAQ NMS - GLOBAL MARKET · FATE
-2.79% · -$0.0600 · Vol 1.5M
After hours · updated 16:06:29 ET
Fate Therapeutics Inc
Biotechnology
$2.09
Follow $FATE
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $FATE by emailVeridion Score
BETAHIGH CONF · 6 of 6 factors measuredStale score · Wed Oct 7 · completed session · 25h old · Scheduled each trading day · Markets closed · resumes Fri 9:30 ET · FATE
Methodologysnapshot unavailable for FATE. Cause unavailable.
FATE
Fate Therapeutics Inc
Stale score · Wed Oct 7 · completed session · 25h old · Scheduled each trading day · Markets closed · resumes Fri 9:30 ET
Lower range
Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
32/ 100
Veridion Score
Lower range · HIGH confidence · 6 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: HIGH · 6 of 6 factors measured · Stale score · Wed Oct 7 · completed session · 25h old · Scheduled each trading day · Markets closed · resumes Fri 9:30 ET
Veridion Score History · 90D
Loading score history
AI Analysis
SovereignWhy is FATE moving today?
Sovereign unlock connects news, insider activity, analyst moves, and live price action.
About Fate Therapeutics Inc
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)Listed since
2013
Employees
161
Country
US
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
Key statistics
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Open
$2.12
Day high
$2.13
Day low
$2.03
Previous close
$2.15
52W high
$3.11
-32.80% from high
52W low
$0.9640
52% of range
Market cap
$257.6M
EPS
$-1.0530
Beta
2.07
Shares out
119.8M
Volume
1.5M
1.03× rel vol
Avg volume
1.4M
VWAP
$2.10
Price history computed in-house
1W
-9.13%
1M
-16.40%
3M
-32.58%
1Y
+38.41%
YTD
+112.70%
SMA 50 $2.47 · below
SMA 200 $1.88 · above
52W position 52%
FATE overview
Related filings and maps
Public disclosures
Congress activity in FATE
1 filers · 0 buys · 1 sells (0 labeled S (partial)) · Jan 31, 2023 to Jan 31, 2023 · House 1 / Senate 0
All available history · Latest 1 of 1 lines · Read 2026-10-08T23:10:37.585Z
Official filing ↗
Federal contracts
FATE contract awards, year to date.
Public federal awards linked to this ticker.
Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for FATE in this window.
Lobbying spend
FATE lobbying filings, year to date.
Registered lobbying filings matched to Fate Therapeutics Inc.
Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for FATE in this window.
Analyst ratings
Sovereign unlock shows live analyst consensus for FATE.
Options
Options data is temporarily unavailable. Changing your plan will not restore the upstream feed.